|
Jele -> RE: Vakcine Prevnar i Pneumokok (24.1.2011 13:48:27)
|
Mihi se ne javlja, pa da podignem temu...
Evo sad ćčitam pojavila se unapređena verzija Prevnara šireg spektra zaštite, Prevnar 13:
Invasive pneumococcal disease (IPD) is still out there...
IPD includes meningitis, which remains a serious risk for children up to age 5. Untreated, meningitis can cause deafness and long-term brain damage. Even children who received the full 4-dose series of Prevnar® might not be covered against 6 additional strains of bacteria that cause IPD.
...but so is more coverage for your child
That's where Prevnar 13® can help. Doctors at the Centers for Disease Control and Prevention (CDC) recommend that children under age 5 be vaccinated with Prevnar 13®.
A single dose of Prevnar 13® may be given to children 15 months to age 5 who have had 4 doses of Prevnar® to get additional coverage.
The immune response from this schedule might be lower for the 6 additional strains (types 1, 3, 5, 6A, 7F, and 19A) than if your child had received the full 4 doses of Prevnar 13®. It's not known how medically important this difference is.
If your child has started receiving Prevnar®, your child's doctor can switch to Prevnar 13® at any point for the remaining doses.
Ask your child's doctor today about additional coverage with Prevnar 13®.
INDICATION FOR PREVNAR 13®
Prevnar 13® is a vaccine approved for use in children 6 weeks through 5 years of age (prior to the 6th birthday).
Prevnar 13® is indicated for active immunization for the prevention of invasive disease caused by 13 strains of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F).
Prevnar 13® is also indicated for the prevention of otitis media (ear infection) caused by 7 strains of Streptococcus pneumoniae (4, 6B, 9V, 14, 18C, 19F, and 23F). No efficacy data for ear infections are available for strains 1, 3, 5, 6A, 7F, and 19A.
IMPORTANT SAFETY INFORMATION FOR PREVNAR 13®
Prevnar 13® should not be given to anyone with a severe allergic reaction to any component of Prevnar 13®, Prevnar® or any diphtheria toxoid–containing vaccine.
Prevnar 13® may not protect all individuals receiving the vaccine.
Protection against ear infections is expected to be less than that for invasive disease.
Children with weakened immune systems may have a reduced immune response to Prevnar 13®.
A temporary pause of breathing following vaccination has been observed in some infants born prematurely.
The most commonly reported serious adverse events include bronchiolitis (an infection of the lungs) (0.9%, 1.1%), gastroenteritis (inflammation of the stomach and small intestine) (0.9%, 0.9%), and pneumonia (0.9%, 0.5%) for Prevnar 13® and Prevnar®, respectively.
The most common side effects are redness, swelling and tenderness at the injection site, fever, decreased appetite, irritability, increased sleep, and decreased sleep. Any side effects associated with the vaccination should be reported to your child's health care provider.
Ask your child's health care provider about the risks, benefits and if Prevnar 13® is right for your child.
http://www.glassrbije.org/info/index.php?option=com_content&view=article&id=10161:vakcina-protiv-pneumonije-moe-da-sprei-i-smrt-od-gripa&catid=43:oko-nas&Itemid=58
|
|
|
|